3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Endometrial Neoplasms
7
Ovarian Neoplasms
6
Neoplasms
6
Uterine Cervical Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
3
Rectal Neoplasms
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Head and Neck Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Lung Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Neuroendocrine
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Turcot syndrome
1
Small Cell Lung Carcinoma
1
Sarcoma, Clear Cell
1
Sarcoma
1
Recurrence
1
Penile Neoplasms
1
Pathologic Complete Response
1
Neoplasms, Second Primary
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
MMRd/MSI-H Stage II-III Endometrial Cancer
1
Interventions
Cisplatin
24
Paclitaxel
18
Carboplatin
18
pembrolizumab
12
Gemcitabine
12
Radiotherapy
9
Fluorouracil
9
Specimen Handling
8
Magnetic Resonance Spectroscopy
7
cemiplimab
6
Platinum
6
Nivolumab
6
Docetaxel
6
Cetuximab
6
1,2-diaminocyclohexaneplatinum II citrate
6
epothilone B
5
anlotinib
5
Sunitinib
5
Pemetrexed
5
Oxaliplatin
5
Everolimus
5
Drug Therapy
5
Cyclophosphamide
5
Capecitabine
5
Bevacizumab
5
durvalumab
4
Radiotherapy, Intensity-Modulated
4
Radiation
4
Erlotinib Hydrochloride
4
Celecoxib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma
×
dostarlimab
×
Clear all
NCT06317311
2025-07-25
RUBY-J
GlaxoSmithKline
Phase 2
Active not recruiting
41 enrolled